An Alternative to Traditional Sample Size Determination for Small Patient Populations

References

• Barnett, H. Y., Villar, S. S., Geys, H., and Jaki, T. (2021), “A Novel Statistical Test for Treatment Differences in Clinical Trials using a Response Adaptive Forward Looking Gittins Index Rule,” Biometrics. DOI: 10.1111/biom.13581.
   PubMed Web of Science ®Google Scholar
• Charan, J., and Biswas, T. (2013), “How to Calculate Sample Size for Different Study Designs in Medical Research?” Indian Journal of Psychological Medicine, 35, 121–126. DOI: 10.4103/0253-7176.116232.
   PubMedGoogle Scholar
• Cheng, Y., Su, F., and Berry, D. A. (2003), “Choosing Sample Size for a Clinical Trial using Decision Analysis,” Biometrika, 90, 923–936. DOI: 10.1093/biomet/90.4.923.
   Web of Science ®Google Scholar
• Colton, T. (1963), “A Model for Selecting One of Two Medical Treatments,” Journal of the American Statistical Association, 58, 388–400. DOI: 10.1080/01621459.1963.10500853.
   Web of Science ®Google Scholar
• Day, S., Jonker, A. H., Lau, L. P. L., Hilgers, R.-D., Irony, I., Larsson, K., Roes, K. C., and Stallard, N. (2018), “Recommendations for the Design of Small Population Clinical Trials,” Orphanet Journal of Rare Diseases, 13, 1–9. DOI: 10.1186/s13023-018-0931-2.
   PubMed Web of Science ®Google Scholar
• Faber, J., and Fonseca, L. M. (2014), “How Sample Size Influences Research Outcomes,” Dental Press Journal of Orthodontics, 19, 27–29. DOI: 10.1590/2176-9451.19.4.027-029.ebo.
   PubMedGoogle Scholar
• fminbnd (2016), MATLAB version 9.0.0.341360 (R2016a). Natick, MA: The MathWorks Inc. Available at https://uk.mathworks.com/help/matlab/ref/fminbnd.html: fminbnd.
   Google Scholar
• fmincon (2016), MATLAB version 9.0.0.341360 (R2016a), Natick, MA: The MathWorks Inc. Available at https://uk.mathworks.com/help/optim/ug/fmincon.html: fmincon.
   Google Scholar
• Hu, F., and Rosenberger, W. F. (2006), The Theory of Response-Adaptive Randomization in Clinical Trials (Vol. 525), Hoboken, NJ: Wiley.
   Google Scholar
• Jovic, G., and Whitehead, J. (2010), “An Exact Method for Analysis Following a Two-Stage Phase II Cancer Clinical Trial,” Statistics in Medicine, 29, 3118–3125. DOI: 10.1002/sim.3837.
   PubMed Web of Science ®Google Scholar
• Kaptein, M. (2019), “A Practical Approach to Sample Size Calculation for Fixed Populations,” Contemporary Clinical Trials Communications 14, 100339. DOI: 10.1016/j.conctc.2019.100339.
   PubMed Web of Science ®Google Scholar
• Korn, E. L., and Freidlin, B. (2017), “Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements,” JNCI: Journal of the National Cancer Institute, 109, djx013. DOI: 10.1093/jnci/djx013.
   PubMedGoogle Scholar
• Lieberman, J. A. (2001), “Hypothesis and Hypothesis Testing in the Clinical Trial,” Journal of Clinical Psychiatry, 62, 5–10.
   PubMed Web of Science ®Google Scholar
• MATLAB (2016), version 9.0.0.341360 (R2016a), Natick, MA: The Mathworks, Inc.: MATLAB.
   Google Scholar
• Merkel, P. A., Niles, J., Jimenez, R., Spiera, R. F., Rovin, B. H., Bomback, A., Pagnoux, C., Potarca, A., Schall, T. J., Bekker, P., and CLASSIC Investigators. (2020), “Adjunctive Treatment with Avacopan, an Oral c5a Receptor Inhibitor, in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis,” ACR Open Rheumatology, 22, 662–671. DOI: 10.1002/acr2.11185.
   Google Scholar
• O’Brien, P. C., and Fleming, T. R. (1979), “A Multiple Testing Procedure for Clinical Trials,” Biometrics, 35, 549–556. DOI: 10.2307/2530245.
   PubMed Web of Science ®Google Scholar
• Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Sydes, M. R., Villar, S. S., Wason, J., Weir, C., Wheeler, G., Yap, C., and Jaki, T. (2018), “Adaptive Designs in Clinical Trials: Why use them, and How to Run and Report Them,” BMC Medicine, 16, 1–15. DOI: 10.1186/s12916-018-1017-7.
   Web of Science ®Google Scholar
• Pocock, S. J. (1977), “Group Sequential Methods in the Design and Analysis of Clinical Trials,” Biometrika, 64, 191–199. DOI: 10.1093/biomet/64.2.191.
   Web of Science ®Google Scholar
• Senn, S. (2016), “Mastering Variation: Variance Components and Personalised Medicine,” Statistics in Medicine, 35, 966–977. DOI: 10.1002/sim.6739.
   PubMed Web of Science ®Google Scholar
• Sibbald, B., and Roland, M. (1998), “Understanding Controlled Trials. Why are Randomised Controlled Trials Important?,” BMJ: British Medical Journal, 316, 201. DOI: 10.1136/bmj.316.7126.201.
   Web of Science ®Google Scholar
• Stallard, N., Miller, F., Day, S., Hee, S. W., Madan, J., Zohar, S., and Posch, M. (2017), “Determination of the Optimal Sample Size for a Clinical Trial Accounting for the Population Size,” Biometrical Journal, 59, 609–625. DOI: 10.1002/bimj.201500228.
   PubMed Web of Science ®Google Scholar
• Tonkens, R. (2005), “An Overview of the Drug Development Process,” Physician Executive, 31, 48–52.
   Google Scholar
• Whitehead, J. (2002), “Sequential Methods in Clinical Trials,” Sequential Analysis, 21, 285–308. DOI: 10.1081/SQA-120016303.
   Google Scholar
• Whitehead, J., and Stratton, I. (1983), “Group Sequential Clinical Trials with Triangular Continuation Regions,” Biometrics, 39, 227–236. DOI: 10.2307/2530822.
   PubMed Web of Science ®Google Scholar
• Williamson, S. F., Jacko, P., Villar, S. S., and Jaki, T. (2017), “A Bayesian Adaptive Design for Clinical Trials in Rare Diseases,” Computational Statistics & Data Analysis, 113, 136–153.
   PubMed Web of Science ®Google Scholar
• Yates, M., and Watts, R. (2017), “ANCA-Associated Vasculitis,” Clinical Medicine, 17, 60–64. DOI: 10.7861/clinmedicine.17-1-60.
   PubMed Web of Science ®Google Scholar